The PGAM5 Knockout AGS Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from AGS human gastric adenocarcinoma epithelial cells, engineered for targeted disruption of the PGAM5 gene. This knockout product delivers a heterogeneous cell pool with PGAM5 loss-of-function, suitable for robust functional studies free of clonal selection bias. It enables investigation of PGAM5-dependent processes in mitochondrial biology and cell death signaling. The polyclonal format provides a representative genetic background for high-throughput screening and mechanistic analyses, supplied as ready-to-use knockout cells for biomedical research.
The AGS cell line originates from a gastric adenocarcinoma of a 54-year-old Caucasian female, serving as a prevalent model for gastric cancer biology. AGS cells exhibit hallmark features of gastric epithelial malignancy, including dysregulated cell signaling, apoptosis resistance, and differential drug sensitivity. Their well-characterized background and standardized culture conditions facilitate genetic manipulation and functional analyses. This line is widely used for studying oncogenic pathways such as Wnt/??-catenin signaling and therapeutic vulnerabilities, providing a clinically relevant context for dissecting PGAM5 functions in gastric carcinogenesis.
PGAM5 encodes a mitochondrial serine/threonine phosphatase that integrates stress signals to regulate mitochondrial dynamics, mitophagy, and cell death. Activated by mitochondrial stress, ROS, and TNF receptor stimulation via RIPK3, PGAM5 dephosphorylates DRP1 at Ser637 to promote mitochondrial fission and dephosphorylates RIPK1/RIPK3 to modulate necroptosis. It interacts with the PINK1/Parkin pathway and dephosphorylates mitophagy receptor FUNDC1, while also regulating oxidative stress through NRF2-KEAP1 crosstalk. PGAM5 further interfaces with BCL2 family members to influence apoptosis. Consequently, PGAM5 functions at the intersection of necroptosis (TNF-R1/RIPK1/RIPK3/MLKL), mitophagy (PINK1/Parkin/FUNDC1), and mitochondrial fission (DRP1/MFF).
In AGS gastric cancer cells, PGAM5 knockout enables analysis of mitochondrial phosphatase signaling in gastric tumor biology. Gastric adenocarcinomas often exhibit aberrant cell death and mitochondrial dysfunction; PGAM5 has been linked to gastric cancer cell survival and drug resistance. The polyclonal knockout population allows assessment of necroptosis induction, mitophagy flux, and mitochondrial morphology in a heterogeneous setting mimicking tumor heterogeneity. PGAM5 loss may sensitize cells to necroptotic stimuli or impair quality control, highlighting therapeutic opportunities. This model also facilitates investigation of PGAM5-regulated oxidative stress responses and Wnt/??-catenin crosstalk, providing an isogenic platform for validating PGAM5 as a gastric cancer target.
Applications include mitochondrial dynamics and cell death studies using immunofluorescence for mitochondrial morphology, mitophagy flux assays, and necroptosis detection (PI, LDH). It supports drug target validation and modulator screening for necroptosis and mitophagy pathways. Western blotting, RT-qPCR, and phospho-analysis monitor dephosphorylation of substrates like DRP1 (Ser637) and RIPK1. Oxidative stress responses can be probed via ROS measurements and NRF2 activation. The AGS background further enables gastric cancer-specific chemosensitivity and signaling studies. For protocols or technical support, contact Ascent Research.
